An open label, multi-center, Phase IV rollover protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or a study of ruxolitinib in combination with either panobinostat (LBH589) or siremadlin (HDM201) or rineterkib (LTT462), and are judged by the investigator to benefit from continued treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515283-31-00

Acronym

CINC424A2X01B

Enrollment

Registered

2024-09-11

Start date

2015-07-30

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study is designed to accept patients with varied disease origins, depending on the parent protocol

Brief summary

Frequency and severity of SAEs/AEs

Detailed description

Proportion of patients with clinical benefit as assessed by the investigator at scheduled visits, Frequency and severity of AEs / SAEs, Proportion of patients with clinical benefit and assessed by the investigators at scheduled visits

Interventions

DRUGJakavi 15 mg tablets

DRUGFarydak 15 mg hard capsules

DRUGJakavi 20 mg tablets

DRUGJakavi 10 mg tablets

DRUGHDM201

DRUGFarydak 10 mg hard capsules

DRUGJakavi 5 mg tablets

DRUGRUXOLITINIB

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency and severity of SAEs/AEs	—

Secondary

Measure	Time frame
Proportion of patients with clinical benefit as assessed by the investigator at scheduled visits, Frequency and severity of AEs / SAEs, Proportion of patients with clinical benefit and assessed by the investigators at scheduled visits	—

Countries

Germany, Italy, Poland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026